Kirk A James, Craig N Burkhart† & Dean S Morrell †UNC School of Medicine - Dermatology, 410 Market Street, Suite 200 Chapel Hill, NC 27516, USA Acne vulgaris is a common skin disorder that affects most individuals at some point in their lives.

Although there have been studies that have been conducted in vitro that show increased resistance of P. acnes colonies to certain antibiotics, it is impor- tant to note that this bacteria is thought to exist as a biofilm within the pilosebaceous unit in vivo, not as a freely mobile microorganism [7].

Recently, with the discovery that P. acnes can create and exist as a biofilm, it is thought that the secreted glycocalyx polymer can actually become incorporated into the sebum composition and act as biological glue between keratinocytes, and thus, ultimately lead to the production of comedones [32].

In one study, topical erythromycin preparations combined with zinc and applied twice daily reduced the acne severity grade and papule count in comparison to using placebo, and was just as effective as using oral tetracycline twice a day [59].

Recent research suggests that the benzoyl peroxide free radicals are more highly active in the presence of a chemical compound that possesses a tertiary amine within its structure, including the antibiotics clindamycin and erythromycin [71].

All patients were satisfied with the active treatment and none experienced adverse effects.

... controlled study of appro priate size; d III Evidence from well designed trials without randomization, single group pre/post, cohort, time series, or matched case controlled studies; d IV Evidence from well designed nonexperimen ...

In addition, very few studies have compared light based treat ments with standard and well validated pharma ceutical treatments and none with the current recommended therapy for most types of acne combination therapy with a topical ...

Nonetheless, it seems that the use of lasers and light therapy alone or with photosensi tizers offer promise.

... SEARCH RE PORT Information on patent family members International application No PCT/US20 1 0/04367 1 Publication Patent family date member(s) Patent document cited in search report Publication date I I I us 20071 22435 NONE ...

Summer AAD, Boston, MA July 2009 “Promiseb™ Topical Cream for the Treamtent of Mild to Moderate Seborrheic Dermatitis of the Face – A Pilot Study” Michale Jarratt M.D., James DelRosso M.D., Zoe Draelos M.D, Steven Kempers M.D., Leon Kircik M.D., Lawrence Parish M.D., Alan Mentor M.D., Boni Elewski M.D.

EADV, Istanbul Turkey, May 2008 “Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% Cream Without Compromising Efficacy in Patients with Acne Vulgaris” Emil Tanghetti M.D., Zoe Draelos M.D., Pearl Grimes M.D., Sunil Dhawan M.D., Michael Gold M.D., Leon Kircik M.D., Lawrence Green M.D., Angela Moore M.D., Fran Cook-Bolden M.D.

32nd Annual Hawaii Dermatology Seminar, Waikoloa, HI, March 2008 Promiseb™ Topical Cream for the Treamtent of Mild to Moderate Seborrheic Dermatitis of the Face – A Pilot Study” Michale Jarratt M.D., James DelRosso M.D., Zoe Draelos M.D, Steven Kempers M.D., Leon Kircik M.D., Lawrence Parish M.D., Alan Mentor M.D., Boni Elewski M.D.

International Academy of Cosmetic Dermatology, Melbourne, Australia, December 2006 “Utilization of Narrow-Band UVB Light Therapy and Etanercept for the Treatment of Psoriasis (UNITE): Efficacy, Safety, and Patient-Reported Outcomes” Leon Kircik, Jerry Bagel, Neil Korman, Alan Menter, Craig A. Elmets, John Koo, Yu-Ching Yang, Chiun-Fang Chiou, Frank Dann, Seth R. Stevens EADV Rhodes, Greece, October 2006 “A Double-Blind, Randomized, Vehicle-Controlled Trial to Determine the Efficacy and Safety of Hydrocortisone Butyrate 0.1% Lipocream in the treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects William Abramovits, M.D., Elizabeth Alvarez-Connelly, M.D., Debra Breneman, M.D., Alicia Bucko, M.D., Zoe Draelos, M.D., Lawrence Eichenfield, M.D., Michael Jarratt, M.D., Candice Johnson, M.D., Steven Kempers, M.D., Leon Kircik, M.D., Robert Loss, M.D, Robert Matheson, M.D., Elaine Siegfried, M.D., Dow Stough, M.D., Hector Wiltz, M.D.

Sun City, South Africa Sept. 2014 “New Treatment in Psoriasis” DEF NPPA Meeting Las Vegas, NV July 2014 “Treatment of Erythema in Rosacea” Spring EADV Belgrade, Serbia May 2014 “Topical Ivermectin” Innovations in Acne and Rosacea Monte Carlo, Monaco May 2014 “Importance of Vehicles” Derm Update Toronto, Canada April 2014 “What’s New in Medicine Cabinet”

- All articles and notices for publication, general correspondence, and inquiries should be addressed to the Editor, Department of Microbiology, Faculty of Medicine, Siriraj Hospital (Phone 4110241ext.

- For the type of material acceptable for this journal, and information regarding the processing of manuscripts, proofs, read "A Guide for Contributors' which is published in the January issue cf the J. Med.

This material may be protected by Copyright law (Title 17 U.S. Code) Incidence of Anemia in Leprosy Patients Treated with Dapsone* Siripen Puavilai, M.D., ** Saengsuri Chutha, M.D., ** Niwat Polnikom, M.D., ** Penwadee Timpatanapong, M.D., ** Pariya Tasanapradit, M.D., ** Somyot Charuwichitratana, M.D., ** Achara Boonthanom, M.D.

These included complete blooo count (CBC), urinalysis, stool examination, reticulocyte count, methemoglobin, Heinz body, Conmbs' test, blood urea nitrogen (BUN), creatinine, lactic dehydrogenase (LDH), serum g!utamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transa minase (SGOT), total protein, albumin, bilirubin and urine hemosiderin pigment.

These findings contrasted with the previous that studies done by De Gowin who demonstrated normal G-6-PD patients could take 100 mg dapsone per day without easily detectable hemolysis<6l.

4 March 2008 Information Exchange System Alert No_ 117 Antimalarial chlorproguanil-dapsone (LapDapTJ\1) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (DacartTM) versus artemether-lumefantrine (Coartem®) and confirmation of findings in a comparative trial of LapDap™ versus Dacart T M GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) have decided to tenninate the fmther development ofDaca1t™, a fixed-dose combination antimalarial product of chlorproguanil, dapsone and a1tesunate (CDA).

However, several CD (LapDapTM) phase IV studies which sta1ted in African countries did not continue beyond April 2006 due to low utilization of this medicine.

Research on the safety aspects mainly continued as pait of the Medicines for Malaria Venture (MMV)- sponsored studies on chlorproguanil-dapsone-aitesunate (CDA).

In total, 15 patients had severe post-treatment haemolysis requiring blood transfusion in the study: all 15 were in the CDA treated group, 13 of whom were G6PD deficient.

2. Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated fakiparnm malaria in Afi-ica: Repo1t of a Technical Consultation convened by the World Health Organization.

It has been proven safe, presenting none of the hematologic 1 risks associated with oral dapsone Data suggest the ve icle formulation enhances healing and contributes to tolerability, making topical dapsone 5% gel a w orthwffi e ...

Nonetheless, these variations are within the scope of the invention, as the lightly- to moderately-crossl inked PVPs thicken low pH compositions.

Almirall, LLC Exhibit 2002 Page 38 DN 3168 P3 Table 5: Discomfort/sting intensity scale used in Example 10 numerical scale rating volunteer perception 0 0.5 1.0 1.5 2.0 2.5 3.0 none barely perceptible slightly perceptible definitely ...